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Abstract:

The ret proto-oncogene encodes a transmembrane receptor tyrosine kinase that plays a
key role in neural differentiation as well as development of the enteric nervous system
and kidneys. RET is activated through interaction with members of the ligand-binding
co-receptors GFRa 1-4 and its corresponding neurotrophic factors consisting of Glial
Cell Line Derived Neurotrophic Factor (GDNF), neurturin (NTN), artemm (ART), or
persephin (PSP) forming a heterodimer structure. Upon activation, RET undergoes
autophosphorylation at select tyrosine residues in the intercellular catalytic domain,
creating docking sites for proteins involved in signal transduction. While several
laboratories have studied the activation of RET, little is known about how the receptor is
inactivated after ligand binding. Mutations of the RET gene have been associated with
several cancers such as MEN2A, MEN2B and FMTC_suggesting that the activated form
of RET has somehow bypassed down regulation. In order to analyze the effect of the
mutated form of RET on signal transduction and downregulation, VERO cells were
transfected with wild type and activated forms of RET and the effect of RET mutations
on protein degradation analyzed. The degradation studies suggest that MEN2B has a
lower level of protein degradation, and that this decreased degradation rate is due to a
loss of Cbl, a protein known to be involved in receptor tyrosine kinase down regulation.
The connection between decreased MEN2B down regulation and the loss of Cbl provides
a possible explanation for the mutant receptor’s oncogenic potential.
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Introduction:
1. Tyrosine kinases family
The tyrosine kinases superfamily consists of enzymes that use ATP to add
phosphate to the amino acid tyrosine. This tyrosine modification alters substrate’s
function or location of a target protein. In humans 518 kinase genes have been identified,
which accounts for 1.7% of all human genes. Of these 518 genes, 164 of the kinases have
been associated with cancer [47]. Protein tyrosine kinases have 11 conserved
subdomains, which assemble the highly conserved catalytic core [48]. The catalytic core
contains an active site that is surrounded by kinase lobes as well as flexible loops and
domains that serve as binding sites for other proteins such as substrates, cofactors, etc.
[48]. In general, protein kinases participate in many important cellular functions such as
proliferation, differentiation, motility and protein-protein interactions that are important
for proper cellular function or signal transduction cascades [1,47-48].
While the majority of protein kinases participate in some kind of enzymatic
activity, there are some protein kinase that have other functions. In humans, for example,
50 kinases domains are found to be enzymatically inactive; however, these inactive
kinases are conserved in many species including, humans, fly and yeast, which suggests
that they play non-enzymatic roles [47]. There are suggestions that catalytically inactive
kinase domains serve as modulators for other enzymatically inactive domains as well as
function as scaffold proteins; other kinases mediate protein-protein interactions. For
instance, 24 kinases contain the SH2 domain. SH2 domain is protein modules composed
of specific amino acid sequences, which are found in many signaling proteins [46]. The
function of SH2 domains is to specifically recognize the phosphorylated tyrosine
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residues, recruit the protein containing the SH2 domain to the tyrosine phosphorylation
sites as well as serve as a docking site for other signaling proteins [47].
The protein kinase family consists of large sub-families; receptor tyrosine kinases are one
of them.

1.1. Receptor tyrosine kinases: structure and role in cell signaling
Receptor tyrosine kinases are a large group of cell surface receptors with
cytoplasmic tyrosine kinase activity. Specifically, they catalyze the reaction in which the
gamma phosphate of an ATP molecule is transferred to the hydroxyl groups of tyrosine
on the target protein [50]. Receptors tyrosine kinases play a critical role in many cellular
functions including cell differentiation and proliferation, cell migration and survival [1,
49]. The general structure of receptor tyrosine kinases includes a glycosylated ligand
binding domain that is connected to an intracellular domain through a single hydrophobic
transmembrane. The cytoplasmic domain contains both a catalytic domain as well as
regulatory domains [50].
The majority of tyrosine kinases appear in the cell as monomeric units that
undergo dimerization upon ligand binding. This dimerization then results in
autophosphorylation in the intracellular domain [50]. These phosphorylation events are
important for both tyrosine kinase activity as well as the ability to recruit other signaling
proteins [50].
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1.2 Proteins that are activated by receptor tyrosine kinases
Signaling cascades are based on protein-protein interactions that result in a variety
of cellular responses. Phosphorylation plays a key role in signal transduction by creating
docking sites for other signaling proteins by interacting with their interaction domains. In
general, interaction domains are specific amino acid sequences that can be defined as a
separate unit of a protein. These specific domains may recognize distinct residues on a
target protein by phosphorylation. The interactions of different domains with the
phosphorylated residues on the target protein may affect the activity, location and
protein-protein interactions that are important for proper protein function or continuation
of signal transduction. For example, previous studies have confirmed that
phosphotyrosine residues of receptor tyrosine kinases can serve as docking sites for
proteins containing SH2 or PTB domains [51, 53], Specifically, SH2 domains bind to a
phosphorylated tyrosine in a specific area in the carboxy-terminal. PTB domains, on the
other hand, bind to phosphorylated tyrosine residues in the N-terminus. Some PTB may
also recognize non phosphorylated residues [50]. The SH3 domain binds to the prolinerich sequence that contains PXXP motif, in contrast, WW domains bind also to a proline
rich region, but it should contain PXPX motif [50]. Another domain that is important for
recruiting proteins to different membranes and specifies the localization is the Pleckstrin
Homology, PH, domain.
The binding of interaction domains create interaction sites for various docking
proteins that contribute to signal transduction cascade.
For instance, docking proteins bind to the SH2 domain through binding sites that
they contain, while others such as GAB1 have PH domain that helps to recruit the
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docking protein to the cell surface. Some docking proteins contain PTB domains that help
them to interact with cell surface receptors [50]. Docking proteins recruit signaling
proteins and contribute to overall signaling proteins that were recruited by the receptor
tyrosine kinase [50-52]. Signaling proteins are activated by receptor tyrosine kinases and
continue the signal cascade. The ability of signaling proteins to be recruited to the cell
surface is one of the important events for generating a signal cascade. For example,
Platelet-Derived Growth Factor PDGF, which is a receptor tyrosine kinase induces
activation of PI3 which generates second messengers known as Ptdlns, P2 and Ptdlns, P3.
These second messengers activate other protein kinases, PDK1 and PKB which plays a
critical role in many biological responses such as cell survival and protein synthesis [50].
Both PKD1 and PKB utilize their PH domain to be recruited to the membrane thorough
interaction with Ptdlns P3 and PI3 kinase products [50-51].
Another important signal cascade that receptor tyrosine kinases participate in is
Ras/MAPK. Ras, a G protein, that interacts with important effector proteins such as Raf
and PI3 kinase and stimulates a large number of cellular responses including cell growth
and division. Ras is activated indirectly by receptor tyrosine kinase. Specifically, Ras is
activated by interactions with guanine nucleotide exchange factor, Sos, that mediates the
exchange of GTP to GDP. In order to activate Ras, Sos needs to be translocated to the
membrane. This movement results by the interaction of Sos with a SH3 domain of an
adaptor protein Grb2. As the receptor tyrosine kinase gets activated, Grb2/Sos complex is
recruited to the membrane through binding of the SH2 domain to a specific
phosphorylated tyrosine residue in the cytoplasmic domain, or binding of Grb2/Sos
complex to She that is bound to an activated receptor tyrosine kinase. After being
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recruited to the membrane, Sos stimulates the exchange of GTP to GDP in Ras [50].
Activated Ras interacts with Raf that phosphorylates a key serine residue in the activation
loop of MAPKK. MAPKK activates MAPK by phosphorylation of specific tyrosine and
threonine residues in the activation loop. Upon activation, MAPK is translocated into the
nucleus where it activates transcription factors. MAPK signal cascades are important to
the cell cycle, migration, proliferation, and differentiation [50] and crucial for
neurogenesis [54]. Therefore, receptor tyrosine kinases indirectly affect very important
cellular functions.

2. Protein tyrosine kinase downregulation
2.1. Endocytosis as a regulation o f cell signaling
Endocytosis is one of the primary means to attenuate or decrease a receptor
dependent signal. In general, cell signaling is regulated by the presence or absence of
receptors. As the levels of receptors or in some cases their ligands are reduced through
endocytosis the magnitude of the signal dramatically decreases [20]. Endocytosis is a
form of internalization of materials such as nutrients, cell surface receptors and other
molecules from outside the cell to the intercellular space and serves as an important root
of regulation [20-21]. The best understood method of endocytosis is clathrin-mediated
endocytosis. Clathrin coated endocytic vesicles bud from the plasma membrane and
undergo internalization of membrane associated proteins. Often these receptors can be
recycled by the transport of exocytotic vesicles. A clathrin adaptor protein unit, AP2,
serves as a link between signaling receptors such as receptor tyrosine kinases and
clathrin-coated pits. This interaction is promoted by a direct contact of tyrosine and
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di-leucine motifs on the receptor with AP2, or through adaptor proteins that serve as a
link between signaling receptor and clathrin [20-21].
Receptor tyrosine kinases such as the Epidermal Growth Factors receptors and
many other signaling molecules are internalized through claritin mediated endocytosis
[20-21]. Although claritin-mediated endocytosis is the best-studied system, there are
other routes of internalization of some RTKs, involving non-clathrin-mediated
endocytosis; although how this happens is largely unknown [20-21]. Many current
studies show that there are correlations between endocytosis and cell signaling. Both
control and regulate each other and are part of a large network system [21]. Receptors
are degraded through endocytosis and stored in various intracellular components, where
they can be degraded or recycled [20-21]. Endocytosis is a potential way to signal
termination that will control the duration of the downstream signaling cascade [21,36].
After internalization, receptors are often recycled and returned to the surface ligand free
or sorted for endosomal degradation [21].
2.2 Protein Degradation as Regulatory Mechanism
Ubiquitination is a covalent post transcriptional modification in which ubiquitin is
attached to the substrate via an isopeptide bond between the C-terminus and a specific
lysine residue on the target protein [29-30] that is used as an internalization signal.
Ubiquitin affect other proteins by altering their localization, stability, enzymatic activities
and ability to interact with other proteins [31]. Ubiquitin is a 76 amino acids protein and
it interacts with ubiquitin binding domains of other proteins [25]. In general, in
mammalian cells there are several endocytosis pathways that exist but and not all of them
are regulated by ubiquitination [31]. Based on previous studies, internalization of the
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receptors does not require ubiquitination, but it can serve as a signal for the clathrincoated pit to target a signaling receptor, or can affect the binding ability of a receptor to
the clathrin AP2 complex [21,24-25]. Ubiquitination pathways involve a group of
ubiquitin enzymes which include El ubiquitin-activating enzyme, E2 ubiquitin
conjugation enzyme and E3 ubiquitin ligase. The ubiquitination pathway is initiated
through the creation of a thioester bond with El ubiquitin-activating enzyme with ATP
dependent ubiquitin [38, 57]. Ubiquitin is then transferred to an E2 conjugate enzyme
which passes the ubiquitin to a target protein mediated by an E3 ligase such as c-Cbl [38,
57]. Ubiquitin itself contains seven lysine residues that can be ubiquitinated to create
diubiquitin and polyubiquitin chains. In particular, chain addition to lysine 48 serves as a
recognition signal for proteasomal degradation [21]. Chain addition to lysine 63, on the
other hand, does not serve as a recognition signal in most cases, but promotes cellular
responses such as endocytic trafficking, inflammatory response, protein translation and
DNA repair. In general, substrates are involved in either monoubiquitination or multimonoubiquitination; both of these ubiquitination types are involved in endocytosis [21].
Polyubiquitination usually promotes the proteasome recognition and degradation of a
protein, while monoubiquitination does not serve as a signal for proteasomal activity
[30]. Ubiquitination is controlled by enzymes, DUBs, that remove the ubiquitin from the
substrate, which later can be recycled. Ubiquitination sites provide additional proteinprotein interaction and contribute to overall cell signaling [31]. For ubiquitination to
occur there should be recognition between ubiquitin and a ubiquitin binding domain on
the substrate. Moreover, mono and poly ubiquitin binds to the ubiquitin binding domain
at very low affinity and requires multiple interactions between ubiquitin, the binding
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domain, and ubiquitin for a sufficient ubiquitination and internalization of a substrate
[31].

2.3. CBL regulates protein tyrosine kinase
As discussed previously, Cbl functions as an E3 ubiquitin ligase that mediates
ubiquitination and results in endosomal internalization and degradation; however, it is not
required for PTK’s signaling abilities [21]. Cbl interacts specifically with activated
PTK’s substrate and serves both as a negative regulator and a positive effector [29-30].
The Cbl family consists of Cbl, Cbl-b and Cbl-c. Both Cbl and Cbl-b have tyrosine
binding domains on their N-terminal, which bind specifically to phosphotyrosine of
activated kinases, a proline rich region with an SH3 domain and a leucine zipper with
strong homology with ubiquitin associated domain. Cbl-c, on the other hand, has a short
proline region and ubiquitin associated domain in the carboxy-terminal that overlap with
leucine zipper motif [38]
All three members of the Cbl family contain a conserved tyrosine kinase binding
domain and RING finger domain [30]. Cbl negatively controls PTK signal by inducing
ubiquitination, which lead to receptor degradation and attenuation of a signal. Both
receptor and non- receptor PTKs phosphorylate Cbl on the tyrosine residues. More
specifically, the association of Cbl with RET occurs indirectly and is mediated through
Grb2 protein. Grb2/Cbl complex recruited via She binds to phosphorylated throsine-1062
that serves as a docking site. Previous studies have shown that mutations in She protein
results in a decrease in ubiquitination and turnover, which results in a prolonged half-life
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of RET. Phosphorylated tyrsosine-1096 that presents only in long isoform, RET51, serves
as a second route for GRB-Cbl recruitment site [2]. Cbl functions asan E3 ubiquitin
ligase that mediates ubiquitination and results in endosomal internalization and
degradation. c-Cbl mediates the attachment of monoubiquitin to receptor tyrosine kinase
which is an essential mechanism for creating docking sites for other proteins that are
important for endocytosis progression. Without c-Cbl activity these interactions would be
weak, not allowing endocytosis progression [39]. An extensive phosphorylation occurs
in various cancer lines. In general, phosphorylation of Cbl allows the binding to the SH2
domains of various signaling proteins. The phosphorylation of c-Cbl occurs on the cterminus of c-Cbl more often on Y700, Y731 and Y774. Substantiated studies suggest
that different domains such as SHI, Abl, and others have a certain affinity to a specific
tyrosine on the c-Cbl, which provides additional regulation and specificity of PTK
signaling [29].

3. RET proto-Oncogene
3.1 RET Structure and Function
The c-ret proto-oncogene encodes a transmembrane receptor tyrosine kinase,
which plays a key role in neural differentiation and survival as well as development of
the enteric nervous system and kidneys. [1-2]. RET is composed of three domains,
including the extracellular ligand binding domain, a transmembrane and intracellular
domain. The extracellular domain is composed of four cadherin like repeats with
putative C a2+ binding sites and cysteine rich regions. Cysteine residues (27 out of 28) are
conserved among species including human, rats, and others, which emphasize the
9

importance of these cysteines in the proper formation of disulfide bonds in the
intracellular domain [1]. The extracellular domain contains glycosylation sites that
become fully glycosylated as RET protein reach its mature form [1, 50]. For wild type
RET the receptor is activated through interaction with members of ligand-binding cell
surface co-receptors GFRa (1 to 4) and their corresponding Glial Cell derived
Neurotrophic Factors ligand family members (GDNF, Neurturin, Artemin, or Persephin)
to form a heterodimeric structure [1-3,18]. As with other RTKS, upon activation, RET
undergoes autophosphorylation of selected tyrosine residues in the cytoplasmic domain,
that is connected to the extracellular domain by a single hydrophobic transmembrane
domain [1,49]. An alternative splicing of the cytoplasmic domain creates three isoforms
of RET protein. Different isoforms differ by the number of amino acids (51, 43 and 9
amino acids) in the carboxy terminus. The isoforms are referred to as RET 51, RET49
and RET9. Often, RET51 and RET9 are co-expressed and are predominant over RET49
[2] and, while most of the autophosphorylation sites are the same for all the splice
variants, there are some differences.
In total, there areló and 18 tyrosine residues in the cytoplasmic region in RET9
and RET51 respectively [1]. Tyr696, Tyr905, Tyr981, Tyrl015, Tyrl062 are
phosphorylated in both isoforms, while Tyrl096 Tyr 1090 are phosphorylated only in
RET51 [1,14, 56]
Phosphorylation of Tyr-905, Tyr-1015, Tyr-1062 and Tyr-1096 in the
intercellular domain have been identified as docking sites for other proteins involved in
signal transduction including Grb7/Grbl0/Grbl4, phospolipase Cy, She and Grb2
respectively [1, 4-5, 8-11, 15,18, 51]. Tyrosine 1062 is required for proper RET
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signaling. Tyrosine 1062 serves as a docking site for docking protein including She,
FRS2 (Fibroblast growth factor receptor substrate), DOK4/5, IRS 1/2 (insulin receptor
substrate) and Enigma (encodes mitochondrial protein), which affects lipid metabolism
[55]. She, serves as a docking site for receptors involving in Ras/MAPK pathway [51].
Thus, RET activates several important signaling cascades that regulate important cellular
functions including cell survival, proliferation, differentiation, migration and many others
[1]. Oncogenic forms of RET can be also activated independently of ligand binding. It
may alter signal transduction through alternation of tyrosine phosphorylation and
substrate specificity [35].
3.2 Regulation o f Apoptosis by receptor tyrosine kinase, RET.
Apoptosis is a naturally occurring process by which cells undergo controlled cell
death. Activation of apoptosis involves series of events within the cell including DNA
degradation and nucleus by group of enzymes called the caspase family of proteases [46].
Normally, the apoptosis program remains inactive within the cell and can be activated by
inducers.
Phosphorylation of tyrosine kinases is a key point of signal transduction. These
post transcriptional modifications may affect many cellular mechanisms including
apoptosis. Specifically, RTKs participate in a large number of pathways that are
important for neuron development [42] as well as promoting cell growth and survival
[43]. Mutations in these proteins typically result in a constitutive activation of these
pathways that lead to a cancer. Activation of receptors tyrosine kinases usually involve an
autophosphorylation event in tyrosine residues that serve as docking sites for other
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proteins such as Grb2 and She. Such pathways stimulate growth and survival [43]. Other
pathways involve programmed cell death that is dependent on a proper function of
protein kinases [42].
Specifically, RET is known to control the differentiation and survival of epithelial
cells as well as neurons and neuroendocrine cells. There is some evidence that RET
induces apoptosis in the absence of GDNF; however, in the presence of GDNF, the
ability of RET to induce apoptosis decrease [44-45]. In was shown that in vitro, caspase-3
cleaves RET and promotes RET induced apoptosis [45]. Recent studies suggest that RET
plays a role in the pituitary cell secreting growth hormones of somatotroph cells. There is
evidence that RET in the absence of GDNF induces apoptosis by increasing Pit-1, a
pituitary-specific transcription factor, levels that leads to evaluates levels of p53, which is
a key player in the apoptosis pathway [44].

4. RET Mutations
Activating point mutations in the RET receptor have been associated with
Multiple Endocrine Neoplasia type 2 (MEN2A and MEN2B) a dominant inherited cancer
syndrome, and familial medullary thyroid carcinoma (FMTC). Loss-of-function
mutations of RET cause the developmental disorder, Hirschsprung disease, a congenital
disorder of the enteric nervous system that is characterized by a congenital absence of
ganglion cells in the distal colon [5-6,12,14, 27, 32].
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4.1. The physiology, molecular biology and cell biology o f MEN2A and FMTC
MEN2A, which counts for more than 75 % of all MEN2 cancers, is characterized
by MTC, Malignant Tumor arising from calcitonin secreting parafollicular C cells; as
well as pheochromocytoma (-50% of the cases) and parathyroid hyperplasia or adenoma
(20-30% of cases). FMTC, which is known as mild form of MEN2A is associated with
medullary thyroid carcinoma only [1,36].
MEN2A and FMTC mutations result from a point mutation in one of the six
conserved cysteine residues including codons 609, 611,618,620, 630 and 634 in the
extracellular domain on RET and additional mutated codons 553,791-891 specific to
FMTC [32]; however, in 90% of all MEN2A cases a point mutation occurs in codon 634
[32] while in FMTC the mutations are more concentrated in codons 609, 618 and 620 [1].
In MEN2A, a point mutation results in RET dimerization by forming intermolecular
disulfide bonds creating homodimers. This dimerization leads to activation of RET
independently from ligand binding, leading to a constant downstream signal [6-7,15-17,
32, 34]. Similarly, FMTC causes RET autophosphorylation in a ligand independent
manner, which increases the activity of other signaling molecules, such as STAT3 [32],
Specifically, a substitution of tyrosine 905 dramatically affects MEN2A kinase activity;
however, substitutions in tyrosine 864 and 952 that are important for a proper MEN2B
kinase activity, has no effect on MEN2A [34].
Moreover, in addition to the molecular differences between different types of
mutations, the cells responses to the mutations differ as well. Specifically, cells
expressing the MEN2A mutation in codon 634 were shown to proliferate more rapidly
and progress more quickly through the cell cycle than mutations in other codons of
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MEN2A and FMTC. In addition, the levels of cyclin D l, the protein responsible for the
G1 to S phase transition was much higher in cells expressing MEN2A and FMCT
compared to wild type RET [32]. Thus, the specific mutations in the extracellular domain
cause a higher proliferation of MEN2A and FMCT compared to other forms of RET.
Previous studies demonstrate that MEN2A and FMCT have higher apoptosis levels
compared to wild type RET, however, FMTC had lower sensitivity to viral induced
apoptosis compared to MEN2A. [32].
Furthermore, alternative splicing between a long isoform of RET, RET51, and a
short isoform, RET9, affects the catalytic abilities of MEN2A, as compared to MEN2B
[34]. Previous studies revealed that the long isoform, RET-51, with MEN2A mutations
has higher catalytic activity (about 1.5 times higher) than the short isoform, RET9 [34].
Therefore, mutations in the extracellular domain that results in the formation of MEN2A
and FMTC have an effect at all levels, including the cellular and physiological response,
as well as a molecular response affecting cell signaling

4.2. The physiology, Molecular Biology and Cell Biology o f MEN2B
MEN2B is the most aggressive form of MEN2, characterized by earlier malignant
tumor formation that is associated with pheochromocytoma (50% of the cases), and other
less frequent but clinically more aggressive phenotypes such as developmental
abnormalities including mucosal neuromas, intestinal ganglioneuromatosis as well as
marfanoid habitus, ocular and skeletal abnormalities [1,36]
Similar to MEN2A, MEN2B induces a constitutive activation of RET activity. However,
unlike MEN2A, MEN2B does not require homodimerization and can remain active as a
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monomeric unit [32-34], MEN2B occurs mostly due to two high specific point mutations
Met918Thr (90% of the cases) and Ala883Phe (10% of the cases) in the intracellular
kinase domain [53] and leads to an alteration in the autophosphorylation site of RET, by
creating newly autophosphoiylation pathways or by deleting the one that already exists
[53], As a result, MEN2B affects substrate specificity [51, 53], Specifically, tyrosine
1096 phosphorylation that occurs only in RET51 isoforms, participates in Grb2 binding
to RET [51]. Mutations in tyrosine 1096 or MEN2B mutations result in a reduction of
Grb2 binding [53]. Therefore, Grb2, known to recruit Cbl, binds less efficiently to the
MEN2B than to the wild type. Moreover, mutations in the tyrosine residues dramatically
affect the kinase activity of mutated forms of RET. Specifically, mutations in tyrosine
1062 dramatically affect the kinase activity as compared to mutations in other tyrosine
amino acids. In contrast to MEN2A, mutations in tyrosine 864 and 952 affect the kinase
activity of MEN2B, while mutations in tyrosine 905, which affects MEN2A kinase
activity, have no effect on MEN2B [34]. There is strong evidence that MEN2B mutations
increase the phosphorylation of tyrosine residue 1062 [32, 34, 51]. The increase in
tyrosine 1062 phosphorylation suggests that MEN2B is more active than wild type RET
or MEN2A in recruiting Sch adaptor and in increasing the levels the of Ras/MAPK
pathway, which may explain the photogenic mechanism of MEN2B when compared to
other forms of RET.
Alternative splicing also affects MEN2B activity. Overall, cells expressing the
long isoform RET 51 with MEN2A and MEN2B have greater activity (about 1.5 and 10
fold higher, respectively) compared to the short isoform RET9 [34].
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In addition to the biochemical differences between MEN2B and wild type RET or
MEN2A, the cellular response to a point mutation in the intracellular domain resulting in
the formation of MEN2B, are much different than wild type RET and other mutated
forms of RET. Specifically, cells expressing either form of MEN2B grew at a
significantly lower rate than cells that expressed MEN2A and FMTC [32]. Moreover, the
levels of cyclin D l, the protein responsible for the G1 to S phase transition was much
lower than the levels in other mutated forms of RET. MEN2B expressed similar
sensitivity to induced apoptosis as compared to FMTC, but much lower sensitivity than
MEN2A. Overall, the induced apoptosis levels in cells expressing MEN2B were lower
than wild type RET [32]. Therefore, while the molecular mechanisms behind these
differences are not fully understood, MEN2B shows significantly different cellular and
physiological responses than compared to other mutated forms, which may explain the
aggressive phenotypes of MEN2B as compared to wild type and other mutated forms of
RET.
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Materials and methods
DNA purification
100 fil of DH5a bacteria was combined with 1 jil DNA of interest (wild type RET initial
concentration 1.34 pg/jiL) and incubated on ice for 15 minutes. Then, the bacteria/DNA
mixture was incubated at 42 ° C for 90 seconds following incubation on ice for 2
minutes. The mixture was placed on LB plates with 50ug/ml ampicillin. The plates were
incubated in 37 ° C overnight. Bacterial colonies that formed were placed in autoclaved
LB- broth (6.25g LB-broth, 250 mL water) and grown overnight. DNA was purified
using a large-scale preparation plasmid kit (Qiagen Inc, USA) per the manufacturer’s
protocol. Specifically, incubated cultures (in 250mL LB-broth) were centrifuged for 10
minutes at 6000 x g. The pellet was re-suspended in lOmL resuspension buffer. 10 mL of
lysis buffer followed by lOmL of neutralization buffer were added to the mixture. The
mixture was centrifuged for 30 minutes at >20,000 x g. The supernatant was moved to a
column that was equilibrated with 10 mL equilibration buffer. The column was washed
with 30 ml washing buffer. 10.5 mL of isopropanol was added to the collection column
and centrifuged for 30 minutes at >15,000 x g. 5 mL of ethanol was added to the pellet,
and centrifuged for 5 minutes at 15,000 x g. Then, the ethanol was removed, and the tube
was air dried. The pellet was collected in 200 pL elution buffer.
The concentration of the DNA was measured by Nanodrop spectrophotometr and DNA
sequencing was performed at Montclair State University.
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Luciferase assay

COS cells were grown in 5% fetal bovine serum (FBS) Dulbecco’s Modified Eagle
Medium (DMEM) at 37 °C in 5% CO2 . The cells were plated in 6 well-dishes for 24
hours prior to transfection. COS cells were co-transfected with 0.5 pg/pl DNA of wild
type, muted forms of RET, kinase inactive form of RET, pcDNA and 0.1 pg/pl of RET
dependent transcription factor,Elk-1 and Ranella and 0.4 pg/pl of GalLuc. Different
forms of RET were transfected using Lipofectamine reagent (Invitrogen, Life
Technologies, Carlsbad, CA). Specifically, after mixing the reagents and DNA, the cells
were serum-starved for 4-6 hours and then the medium was changed to 5 % FBS DMEM.
The cells were incubated for 48 hours at 37 °C with 5% CO2 and then processed for
analysis. The cells were washed with unsterile PBS, 0.5 ml/well. The cells were
incubated in 250 pL of Passive Lysis buffer (Promega, USA) for 15 minutes at room
temperature on the rocker and then collected.
For measurements, 20 pL of each sample was added to 100 pL of luciferase and the
measurements were taken using a luminometer (DLReady, TD-20/20). Ranella levels
were measured by combining 20 pL of a sample with 100 pL of Stop & Glo mixture
containing 30 pi Stop and Glo Substrate and 1.5 mL of Stop and Glo buffer ( Promega).
according to the experimental protocol for the Dual-Luciferase Reporter assay system
(Promega, USA)

18

Cycloheximide treatment
Vero cells were maintained in growth medium consisting of DMEM (Sigma-Aldrich)
containing 5% fetal bovine serum, L-glutamine, 0.2% gentamicin and 1% penicillin/
streptomycin.
For transfection, VERO cells were plated into T25 flasks and transfected the next day
using Lipofectamine (Invitrogen Life Technologies). Cells were serum starved for 4-6
hours post transfection and then the medium was changed to 5% FBS DMEM and
incubated in 37 ° C with 5% C02. An equal amount of total plasmid DNA was used for
each transfection.
VERO cells were placed in serum free DMEM medium for 12 hours prior to
cycloheximide treatment. 100 pg/mL of cycloheximide (Sigma-Aldrich, USA) was added
to T25 flasks containing cells in 5 mL of serum free DMEM at 37 °C with 5% CO2 . The
cells were collected after 8 hours.

Membrane localization
The cells were collected in 1 mL phosphate buffered saline (PBS). Then the cells were
centrifuged at 9500rpm (centrifuge 5415 C, Eppendorf) for 1 min at 4 °C. 900 pL of the
supernatant was removed to a new tube and then centrifuged for 16 minutes at maximum
speed at 4 °C. 100 pL of sample buffer was added to resuspend the pellet. The samples
were stored at -20 °C.

Cell collection, SDS-PAGE and Western Blot analysis

The cells were collected in lmL PBS. The cells were centrifuged at maximum speed for
15 min and 100 pL of 5X sample buffer (3.6mL water, 0.2mL 5% bromphenol blue, 4mL
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5x SDS running buffer, 2 mL glycerol, 0.2 mL beta-mercaphoethanol for a total 10ml of
buffer) was added to the pellet. The samples were stored at -20 °C.
Cell lysate was warm up at 80 °C for 5 min and centrifuged for 15 seconds at maximum
speed at room temperature. The samples were resolved by 7.5% SDS-PAGE (separating
gel: 3.75mL 30% acrylamide/0.8%bisacrylamide solution, 3.75mL 4X Tris-Cl/SDS pH
8.8, water, 200 pL 10% ammonium persulfate and 20 pL TEMED. Stacking gel: 0.65mL
of 30% acrylamide/0.8%bisacrylamide solution, 1.25 mL of 4X Tris-Cl/SDS pH 6.8, 3.05
mL water, 100 pL ammonium persulfate and 10 pL TEMED) for two hours at 150V, and
transferred to a PVDF (Millipore Corporation, USA) membrane. After the transfer
membranes were blocked in 1% Bovine Albumin in (PBS) or Tris Buffered Saline (TBS;
lOmM Tris pH7.5,150mM NaCl) and incubated with the appropriate antibody for 2
hours. After washing with IX Tris, the membranes were incubated in lOmL of IX TBS
with secondary infrared labeled antibody for 1 hr; the membranes were analyzed by
Odyssey infrared imaging system (Li-Core).
The antibodies used were monoclonal anti-HA, antibody produced in mouse (SigmaAldrich) in 1:10,000 dilution, beta-actin anti-Rabbit PAb (NeoMarkers) in 1:10,000
dilution, anti-human Cbl in 1:10,000 dilution (Cascade BioScience, USA), Antiphosphotyrosine in 1:10,000 dilution (Upstate, USA), infrared anti mouse 1:20,000 and
infrared anti rabbit 1:20,000 dilutions (Li-Core).
Relative intensity was measured by Odyssey infrared imaging system as follows: an area
of a band was labeled by a rectangle and an integrated intensity in pixels/millimeter of
area was obtained. The relative intensity is based on the intensity of the bands and
relative background intensity. All the bands were measured using equal area.
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Viral Infection and Apoptosis Assay
VERO cells were transfected into 96 well plates using Lipofectamine reagent as follows:
300ng of pcDNA, wild type RET and MEN2B respectively, were diluted in 25 pL of
DMEM medium without FBS. 0.3 pL of Lipofectamine were diluted in 25 pL of DMEM
medium without FBS. The tubes were combined and incubated at room temperature for
10 minutes. 50 pL of DNA/Lipofectamine mixture were added into each well. All the
samples were done in triplicates. The cells were incubated at 37 ° C for 4 hours. After the
incubation the cells were washed twice with 25 pL of PBS, and 100 pL of 5% FBS
DMEM were added to each well. The cells were incubated for 24 hours. In order to
measure the background levels of luminescence, three wells containing cells in DMEM
medium were not transfected.
16 hours prior to viral infection, the medium was changed to serum free DMEM
(lOOuL/well). Then, 25 pL of Sindbis virus (in medium, kept in -80 ° C) was added to
half of the cells for each DNA sample (3 wells total/sample). The cells were incubated in
37 ° C in 5% CO2 for one hour. After the incubation, the medium was removed and
100 pL of 5%FBS DMEM was added to the cells. The cells were incubated at 37 0 C in
5% CO2 for 5 hours followed by apoptosis assay.
Prior to the apoptosis assay, the caspase-Glo 3/7 buffer (Promega, USA) and substrate
were equilibrated at room temperature. The caspase-Glo 3/7 buffer was transferred to the
caspase-Glo 3/7 substrate and mixed well. The cells were removed from the incubator
and were equilibrated at room temperature before the assay. Then lOOuL of caspase-Glo
3/7 mixture was added to all cells and incubated at room temperature for 30 minutes. The
luminescent readings were done by using a plate-reading luminometer.
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In order to take into account the background luminescence, the average of numeric values
of “Blank” wells (containing cells in DMEM medium and caspase-Glo reagent) was
subtracted from the numeric values of all the samples. The graph was based on the
average and standard deviation of triplicated viral treated and untreated cells.
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Results:

MEN2B has lower downstream transcription potential than wild type RET and MEN2A

To investigate the effect of mutant forms of RET on downstream transcription,
COS cells were co-transfected with wild type or, mutant forms of RET and RET
dependent transcription factor Elk-1. The Elk-1 gene was fused with the DNA binding
domain of the GAL protein and Gal dependent promoter linked to the luciferase gene in
order to decrease any endogenous background signal [60-61]. As a negative control, the
kinase inactive form of RET was also transfected in COS cells. This system allows for
RET dependent transcription to be measured indirectly by measuring the Luciferase
transcription levels. The reporter gene assay demonstrated that wild-type RET increased
transcription over kinase inactive form of RET and MEN2B while MEN2A had greater
downstream potential than wild type and other forms of RET (Figure 1, Table 1).
Therefore, MEN2B has lower levels of protein transcription compared to wild type RET.
These results are consistent with previous experiments demonstrating that the MEN2B
form of RET is a less-active kinase than either wild type or the MEN2A version of RET
(1,59).
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Luciferase Assay

Fig 1: Luciferase assay of transfected Cos cells. MEN2B has lower protein transcription levels than wild
type RET and MEN2A.

DNA

LUC

WtRET

1131
428.3
1163
53.25
134.7
73.7
274.5
497.2
1590
706.8
284.9
161.7

Ki-

MEN2A

MEN2B

Luciferase assay 08-02-2008
Standard
LUC/RAN
Average
deviation
0.188978
0.672014 0.873501
1683
0.901684
475
1.046805
1111
0.372717
0.700381 0.270016
76.03
0.052088
2586
0.057578
1280
1.741604
475.4
0.577408 1.417666
0.255498
1946
3.42009
464.9
0.557581
0.715366
1.248984
565.9
0.760545
374.6
0.136571
1184
RAN

Table 1: Raw data-Luciferase experiment The samples were measured in
triplicates. The averages were measured based on the ration o f luciferase over
ranella.

Measurements o f protein degradation using cycloheximide treatment
Given that the MEN2B version of RET is less active transcriptionally than wild
type RET, another possible reason for MEN2B patients display a more severe phenotype
could be related to the stability of the mutant protein itself. To investigate protein

24

degradation of the wild type and muted forms of RET, COS cells were transfected with
pcDNA, RET, MEN2A and MEN2B. Cells were treated with cycloheximide, which
blocks protein biosynthesis (de novo protein synthesis), for nine hours and then the
membrane was collected and analyzed using SDS-page and Western blot analysis. After
nine hours without new protein synthesis, there is a reduction of protein levels in wild
type RET and MEN2A after cycloheximide treatment, while MEN2B levels remain
unchanged with or without treatment (Figure 2)

Fig2: Protein degradation after cycloheximide treatment. VERO cells were
transfected with pcDNA, wild type RET, MEN2A and MEN2B respectively.
Cells were treated with cycloheximide for nine hours and then the membrane was
collected. There were no bands in pcDNa alone, but we see reduction in protein
levels in treated cells o f wild type RET and MEN 2 A as compared to untreated.
MEN 2B protein levels remain unchanged with or without treatment.

Detailed analysis ofprotein degradation o f wild type RET and MEN2B
In order to confirm these experiments in another cell type, VERO cells were
transfected with pcDNA, wild type RET and MEN2B, respectively. After eight hours of
cycloheximide treatment, the cell lysate was collected. Consistent with the luciferase
results, the level of MEN2B prior to cycloheximide treatment is lower than wild type
RET (Figure 3), However, after treatment, the experimental data obtained from
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membrane isolation and membrane blotting using an infrared antibody detection system,
revealed that upon cycloheximide treatment the levels o f protein in wild type RET
dropped dramatically while MEN2B protein levels did not change equivalently. In order
to obtain a numeric value of the difference in protein levels, relative intensity o f each
band relative to actin as a control was measured. Averages o f results o f three independent
experiments revealed that the initial wild type RET protein levels before cycloheximide
treatment was about three fold higher than untreated MEN2B (Figure 4). Again, these
results confirm the results of the reporter gene assay, that, in fact, wild type RET is
expressed at higher levels than MEN2B (Figure 1). Moreover, relative intensity analysis
revealed that wild type RET drops in average by six fold after cycloheximide treatment as
compared to MEN2B that drops by less than one fold during the same time o f treatment.

pcDNA.
Cycloheximide treatment

(-)

( “ ")

WTRET
(-)
<-)

ME2C3
0
M

Fig 3: Protein degradation of pcDNA, Wild type RET and MEN2B after
eight hours of cycloheximide treatm ent. Vero cells were transfected with
pcDNA, WTRET and MEN2B using Lipofectamine reagent. After cycloheximide
treatment for eight hours, the whole cell lysate was collected and resolved by SDS
page and Western blot analysis. The images were visualized using Odyssey infra-red
imaging system. After cycloheximide treatment, the levels of wild type RET dropped
while the levels of MEN2B do not change at the same level as wild type RET.
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Analysis of protein degradation in wild type RET and
MEN2B
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Fig 4: Relative intensity of Wild type RET and MEN2B with and without cycloheximide treatment
The results represent the average o f three independent experiments. The value is the ratio of RET
concentration over actin. Analysis of relative intensity was done using Odyssey infra-red imaging system
and was measured as integrated intensity in pixels/millimeter.

Measurements o f Phosphotyrosine levels in wild type RET and MEN2B
In order to analyze phosphorylation levels of tyrosine in MEN2B compared to wild type
RET, cell lysate of pcDNA, wild type RET and MEN2B were analyzed by SDS-Page and
Western blotting analysis. The blots were incubated with anti-phosphotyrosine antibody.
As with the luciferase and RET experiments, MEN2B without cycloheximide treatment
reported lower phospotyrosine levels than wild type RET (Figures 5,6). However, after
cycloheximide treatment, the levels of phosphotyrosine in wild type RET drops
significantly compared to MEN2B (Figure 5). An average of two independent
experiments of relative intensity analysis of phosphotyrosine levels over actin reveals that
the phosphotyrosine levels in wild type RET before cycloheximide treatment are almost
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one fold higher than MEN2B. However, the phosphotyrosine levels in wild type RET
after cycloheximide treatment drop by eight fold compared to MEN2B that drops by less
than one fold (Figure 6).
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Fig: 5: Analysis of phosphotyrosine levels in wild type RET and MEN2B with and without
cycloheximide treatm ent. Cell lysates ofpcDNA, wild type RET and MEN2B were analyzed using SDSPage and Western blot analysis. The blots were blotted with anti-phosphotyrosine antibody. The levels of
phosphotyrosine in wild type RET drop dramatically after cycloheximide treatment. In contrast, the levels
of phosphotyrosine in MEN2B remain unchangeable with or without cycloheximide treatment.

Relative Intensity of Phosphotyrosine/Actin in wild Type
RET and MEN2B

■ phosphoT/Actin

F ig 6 : Relative intensity of phosphotyrosine in wild type RET and MEN2B with and without
cycloheximide treatm ent. The results represent the average of three independent experiments. The value is
the ratio of phosphotyrosine concentration over actin. Analysis of relative intensity was conducted using
Odyssey infra-red imaging system and was measured as integrated intensity in pixels/millimeter.
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Measurement o f ubiquitination levels o f wild type RET and MEN2B
In order to identify a possible link between ubiquitination and either RET or the
mutated forms of RET, the cell lysate was resolved by SDS-Page and Western blot
analysis performed using an anti-human Cbl antibody. The blot was visualized by
Odyssey infrared imaging system. Experimental results show that the level of Cbl in
MEN2B drops after cycloheximide treatment, while in wild type RET the levels of Cbl
remains at similar levels. (Figure 7).

Vector
Cycloheximide: -

WT RET

MEN2B

*

120KB —
WB:Anti-Cbl

Fig 7: Analysis of ubiquitination levels in wild type RET and MEN2B
VERO cells were transfected with pcDNA, wild type RET and MEN2B.
After cycloheximide treatment, the cells were collected and resolved by SDS-Page
and Western blot analysis using anti-human Cbl antibody in 1:10,000 dilution.
Experimental results suggest that the levels of Cbl in MEN2B drop after
cycloheximide treatment, while the levels of Cbl in wild type stays unchangeable
during cycloheximide treatment.

Apoptosis Assay analysis
Apoptosis is controlled cell death. As other important biological processes,
apoptosis is highly regulated. Protein kinases are known to control apoptosis [1,41, 5051]. In order to analyze how apoptosis levels are affected when cells are transfected with
wild type RET and MEN2B a caspase-Glo 3/7 kit was used.
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Experimental results suggest that prior to viral infection MEN2B has lower rate of
apoptosis compared to wild type RET (by 1.2 units lower). After viral infection, caspase
activity increased in all of the samples. However, the apoptosis levels in wild type RET
were still higher compared to MEN2B (by 1.16 units higher). Interestingly, the apoptosis
levels in pcDNA after viral treatment was higher than wild type and RET and MEN2B
(Figure 8). These results suggest that wild type RET and MEN2B have the ability to
reduce the apoptosis levels. Specifically, upon Sindbis virus induction, the levels of
apoptosis increased [39-40]. In the vector alone, there was a significant increase in
caspase activity upon viral induction. However, in wild type RET the increase in caspase
activity did not occur at the same level. These results suggest that transfected cells with
wild type RET are less sensitive to induced apoptosis compared to cells that have been
transfected with vector alone. This indicates that wild type RET is capable of reducing
viral induced apoptosis levels.
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Fig 8: Measurements of apoptosis levels in wild type RET and MEN2B using Caspase-Glo 3/7 kit.
Apoptosis levels were measured indirectly by measuring caspase activity. Experimental results are based
on average of triplicates. Experimental results suggest that wild type RET undergoes higher levels o f
apoptosis compared to MEN2B.
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Discussion:
Activating point mutations in RET have been associated with both types of
Multiple Endocrine Neoplasia type 2 known as MEN2A and MEN2B. While both
MEN2A and MEN2B results from activation mutations of RET, it appears that the two
mutant receptors use unique mechanisms within the cell. MEN2A, for example, is
activated through receptor dimerization caused by intermolecular disulfide bonds [32-34].
MEN2B, on the other hand does not undergo dimerization and appears to be activated
independent of association with either co-receptor or other tyrosine kinases [32-34]. Also,
MEN2B kinase activity appears to be lower than MEN2A even though the MEN2B
mutation has a displays severe phenotype [5-6,12,14,27, 32]. Previous studies suggest
that MEN2B+ cells undergo lower proliferation rates as compared to wild type RET and
MEN2A, which is consistent with the lower kinase activity [32]. However, previous work
has also shown that MEN2B+ cells have lower apoptosis rates.
In order to analyze receptor-dependent transcription activation of MEN2B
compared to wild type RET, a reporter gene assay using a substrate luciferin was
conducted. Specifically, RET dependent transcription factor, Elk-1, was fused with the
DNA binding domain of the GAL protein and co-transfected with a GAL dependent
promoter linked to the luciferase gene. So as transcription takes place, an Ekl-1
dependent promoter linked to a luciferase gene is transcribed. Luciferase, the product of
the luciferase gene, emits light that could be detected by a luminometer. The amount of
the emitted light is proportional to the amount of Elk-1 that has been activated. However,
due to the fact that Elk-1 is a RET dependent transcription factor, activation of Elk-1
indirectly measures RET activation. Therefore, transcription levels were measured
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indirectly by measuring luciferase transcription. A comparison of downstream
transcription in wild type RET and mutated forms of RET, MEN2A and MEN2B
correlates with previous results suggesting that MEN2B is a less active kinase than the
wild type RET, consistent with the previous findings on kinase activity and cell
proliferation. However, this result is inconsistent with the evidence that MEN2B-patients
exhibit a more aggressive phenotype [1, 50]
In order to try and clarify the reason that MEN2B patients have a more severe phenotype
than MEN2A patients even though it appears that MEN2B is a less active kinase, protein
degradation of wild type and muted forms of RET was analyzed. In order to measure this
degradation rate, new protein synthesis was eliminated through the use of cycloheximide.
Cycloheximide works by inhibiting the attachment and the movement of tRNA in to the
donor sites of ribosomes. As a result, peptide initiation and extension are inhibited [58].
Cycloheximide has also been used to study protein stability in measuring RET splice
variants [2]. Specifically, researchers measured the reduction of receptor protein levels in
two different RET isoforms by inhibiting protein synthesis using cycloheximide
treatment [2]. In our experiments the cycloheximide was also used to analyze protein
degradation levels of MEN2B compared to wild type RET.
Knowing that transcription activation in wild type RET is higher than in MEN2B,
it was important to confirm the difference in protein levels of wild type RET and
MEN2B. The levels of protein and the degradation levels were measured using a
cycloheximide treatment. Experimental results revealed that upon cycloheximide
treatment wild type RET and MEN2A protein levels were reduced, suggesting that some
protein degradation is occurring for both mutants. However, the levels of MEN2B
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remains much more stable compared to untreated cells. In order to confirm the
differences in degradation levels of MEN2B in another cell line, VERO cells were
transfected with pcDNA, wild type RET and MEN2B, respectively, and treated with
cycloheximide. Again, our results showed that while the level of MEN2B prior to
cycloheximide treatment was three fold lower compared to wild type RET. Wild type
RET levels were reduced six fold after treatment with cycloheximide while MEN2B
levels dropped by less than one fold. Therefore, there is a critical difference between in
the wild type RET and MEN2B on degradation levels.
After confirming that MEN2B is expressed at a lower rate than wild type RET,
but the protein levels remained almost unchangeable for longer period of time compared
to wild type RET, receptor activity was evaluated by measuring the phosphorylation
levels of MEN2B and wild type RET, pre and post-cycloheximide treatment.
Tyrosine phosphorylation is a key element in RET activity. Upon activation, RET
undergoes a series of tyrosine phosphorylation event in the intracellular domain that
serves as a docking sites for other signaling molecules.
Previous studies demonstrated that MEN2B mutations increase the phosphorylation of
tyrosine residue 1062[32, 34]. Phosphoiylated tyrosine1062 participates in numerous
signaling pathways and serves as an important signal initiator [51-52]. The fact that
MEN2B increase the phosphoiylation in tyrosine 1062 suggests that MEN2B is more
active than wild type RET and MEN2A in recruiting Sch adaptor and increasing the
levels of the Ras/MAPK pathway. In order to analyze the overall levels of
phosphotyrosine in MEN2B compared to wild type RET, anti-phosphotyrosine antibody
was used. The experimental results demonstrate that the ratio of overall tyrosine
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phosphorylation over actin levels (that was used as a base line) in MEN2B is lower than
wild type RET (about one fold). Again, these results demonstrate that overall MEN2B is
less active than wild type RET. However, upon inhibition of protein synthesis using
cycloheximide, the overall phosphotyrosine levels in wild type RET drops eight fold
compared to untreated wild type RET. In contrast, the levels of phosphotyrosine in
MEN2B dropped by less than one fold compared to the untreated sample. These
experimental data suggest that not only is MEN2B degraded more slowly than wild typeRET, it also stays active for longer period of time. The constant activation of MEN2B
may explain the reasons for the aggressive phenotype of MEN2B compared to other
forms of RET. A further analysis of tyrosine phosphorylation using immunoprécipitation
technique will provide more detailed analysis of specific tyrosine phosphorylation on
RET.
The fact that MEN2B is constantly active may suggest that MEN2B has different
levels of signal attenuation compared to wild type RET. Receptor degradation serves as
an important regulatory mechanism to control the duration of signal transduction,
therefore, levels of protein degradation were analyzed by measuring the Cbl levels. Cbl is
a member of the E3-ligase enzymes that help to ligate the ubiquitin protein to a protein of
interest that function in protein degradation [2,29, 38]. Therefore, by measuring the
levels of Cbl in the cells we may estimate the relative ubiquitination levels that occur in
the cells. Cbl is recruited to the receptor through a complex of signaling proteins
Grb2/Sos [50]. Previous studies demonstrated that Grb2 binds less efficiently to the
MEN2B as compared to wild type RET and MEN2A [53]. These results suggest that
MEN2B should have an overall lower rate of ubiquitination than wild type RET.
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Although ubiquitination levels of RET and the RET mutants were not analyzed, analysis
of overall Cbl levels in wild type RET and MEN2B was measured. The analysis of Cbl
levels of wild type RET and MEN2B shows that independently of cycloheximide
treatment, the levels of Cbl remain constant in wild type RET. The level of Cbl in
MEN2B+ cells, on the other hand, drops significantly when protein synthesis was
inhibited. These results suggest that over time the Cbl levels get reduced in MEN2B,
which may explain the reason that MEN2B is not degraded to the same degree as wild
type RET. What is not clear is why Cbl would decrease in these cells. The overall Cbl
level over time is getting reduced while the protein levels and the activity of the receptor
remain at high levels, which may result in a longer acting receptor with more persistent
oncogenic potential. A further analysis of overall ubiquitination in wild type RET and
MEN2B should be measured in order to confirm that overall the ubiquitination levels in
wild type RET differ from MEN2B. Moreover, analysis of other signaling proteins
involved in the ubiquitination pathway can be analyzed in order to better understand the
differences between downregulation of wild type RET and MEN2B.
Lastly, in order to analyze the downregulation of wild type RET and MEN2B,
apoptosis levels were measured. RET, like many other receptor tyrosine kinases
participates in a large number of important cell functions such as cell differentiation,
proliferation, and apoptosis [42]. Previous studies suggest that RET may induce apoptosis
in the absence of GDNF, while the addition of GDNF may decrease the ability of RET to
induce apoptosis [44-45]. Apoptosis is a controlled cell death. Various conditions may
induce apoptosis. As a result, the levels of protein in general may drop. In order to
investigate whether there is a difference in apoptosis levels between MEN2B and wild
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type RET, VERO cells were transfected with pcDNA, wild type RET and MEN2B,
respectively. Apoptosis was induced by viral infection using Sindbis virus and analyzed
using a Caspse-Glo 3/7 Apoptosis assay. Sindbis virus is an enveloped positive strand
RNA virus that is identified as mosquito-borne Alphavirus. Sindbis virus is known to
infect most vertebrate cell lines and kill the cells by inducing apoptosis [39-40]. Previous
studies suggest that the synthesis of viral proteins is essential for inducing apoptosis;
however, the mechanism by which apoptosis is induced is still mainly unknown [40].
The apoptosis levels were measured indirectly using Caspase-Glo 3/7 kit. Caspases play a
key role in apoptosis. Activation of caspases has been shown to increase apoptosis levels
while inhibition leads to a decrease on apoptosis levels [41]. Specifically, Caspase-3
cleaves Bcl-2 and Bel- XLand releases the carboxy-terminai fragments that affect the
ability of these proteins to continue their anti-apoptotic function leading to elevation of
apoptosis levels.
The Caspase-Glo 3/7 Assay kit measures the activity of caspase 3 and 7. The kit
provides a substrate that contains the tetrapeptide sequence DEVD, which optimized for
caspase and luciferase activity. The addition of the substrate mixture (substrate and
buffer) to the cells, results in cell lysis and subsequent substrate cleavage by the caspase
activity. Substrate cleavage results in a luminescent signal, which is proportional to the
caspase activity (Technical Bulletin, Caspase-Glo 3/7 Assay, Promega USA). Thus, by
measuring the levels of caspase activity, a relative apoptosis level may be obtained.
Experimental data demonstrate that the apoptosis levels upon viral infection increase in
all the forms including pcDNA, wild type RET and MEN2B. However, prior to viral
infection, wild type RET has higher apoptosis rate than MEN2B (approximately 1.2 unit
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increase). Moreover, after viral infection the levels of apoptosis in wild type RET remain
higher than MEN2B (by 1.16 unit increase). These experimental data confirm that wild
type-RET is more sensitive to induced apoptosis compared to MEN2B [32]. Thus, the
lower rates of apoptosis and Cbl in MEN2B compared to wild type RET may explain the
oncogenic potential of MEN2B compared to wild type RET. In addition, the apoptosis
levels in the vector alone, after viral induction, is much higher than both wild type RET
and MEN2B, which suggests, that transfected cells with plasmid containing wild type
RET or MEN2B employ mechanisms that lower the apoptosis levels. However, further
analysis should be performed to analyze the possible reasons for low apoptosis levels in
wild type RET and MEN2B and compared to MEN2A.
To summarize, the oncogenic pathway and protein downregulation of MEN2B is
not fully studied. However, the experimental results may provide some explanation for
MEN2B’s oncogenic potential. MEN2B is expressed at a lower rate than wild type RET;
However, the protein level remains at the same levels for a longer period of time and
more importantly, MEN2B retains its activity for a longer period of time as compared to
wild type RET. These, may explain the aggressive phenotypes that have been associated
with MEN2B. In addition, the reduction in Cbl levels and anti-apoptotic abilities of
MEN2B compared to wild type RET, may partially explain the oncogenic potential of
MEN2B as compared to wild type RET. A further analysis of how Cbl gets reduced is
necessary to provide more information about the downregulation and oncogenic potential
of MEN2B.
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